Tagged with Switzerland

Switzerland Helsinn is a leader in cancer supportive care, and Vice Chairman and CEO Riccardo Braglia enthusiastically discusses the Group’s entrance into the field of oncology therapeutics and the launch of the new Helsinn Investment Fund.   Helsinn Advanced Synthesis in Biasca is a very advanced site capable of synthesizing high…

Switzerland With over 50 years of history in Switzerland, Zambon operates in Canton Ticino one of Zambon’s two major global production centers. Swiss Market  Manager Giampiero Roncoroni discusses the unique features of the Swiss market, and how a particular focus on the OTC/OTX market has been a key factor of success…

Switzerland With 40 years of history in Switzerland, B Braun serves every hospital in the country and operates three distinct production sites. CEO Madeleine Stöckli discusses her strategy for improving productivity and finding opportunities for growth. Could you please briefly introduce yourself and B Braun Switzerland to our readers? B Braun…

Switzerland Sintetica, Switzlerland’s longtime leader in local anesthesia and pain relief with development efforts in neuromodulation, started an ambitious internationalization strategy in 2011. CEO Augusto Mitidieri discusses the company’s expansion progress and highlights areas of unmet medical need around anesthetics. What are the most significant unmet medical needs in the realm…

Switzerland The Swiss Biotech Association’s Nic Alexakis describes Switzerland’s thriving biotech scene and extensive support infrastructure, while also highlighting the gaps around early stage funding and the ability of different cantons to collaborate on economic development.  Switzerland of course has quite the reputation as a hub for biotech activity – how…

Actelion Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a total takeover price could top USD 20 billion. As Actelion is a market leader in some therapeutic areas such as pulmonary arterial hypertension (PAH), the acquisition could…

Switzerland Developing manufacturing capacity for as yet unapproved drugs can create huge risk on innovators’ balance sheets, risk which can be mitigated by working instead with a competent CMO – a form of insurance as explained by Siegfried CEO Rudolf Hanko.   The CMO sector has grown faster than the pharma…

Switzerland Specializing in ultra-rare diseases, Alexion targets patient populations of less than 20 patients per million. Christophe Bourdon discusses Alexion’s progress towards developing access for patients across the EMEA region.   Since day one, Alexion’s mission has been to focus solely on discovering treatments for patients affected by these incredibly rare…

Switzerland It is tempting to characterize Switzerland’s global pharma and life science hotspots as beginning and ending with Basel – home of industry giants Roche and Novartis. However, Zurich, Geneva, and even tiny Zug are all now staking serious claims for global recognition in this area. “Zurich is the world’s smallest…

Switzerland Dr. Andrea Michael Meyer, general manager of Sanofi Genzyme Switzerland, reveals how the Swiss business has been experiencing year-on-year double-digit growth; how rare diseases was the foundation of Sanofi Genzyme´s business and remains a key part of their DNA; and how a focus on patient centricity remains at the core…

Switzerland Bernhard Neidhart, head of Office for Economy and Labor in Zug, introduces us to the Canton of Zug and explains how the region became a hotspot for pharma.   To begin Dr. Neidhart, could you please introduce us to the Canton of Zug? How does Zug’s “value proposition” compare to…

Switzerland For the eighth year in a row the World Economic Forum has ranked Switzerland first in both global competitiveness and in innovation; economiesuisse CEO Monika Rühl discusses the main issues which threaten this leading position, and the overall growth prospects for the Swiss economy. To begin, could you please introduce…